Practical Issues with Prescribing ADHD Meds

Topics: Adhansia | ADHD | Aptensio | Contempla | Dyanaval | Evekeo | Jornay PM | Mydayis | Qelbree | Quillivant | Stimulant treatment | Zenzedi and ProCentra

We spoke with Dr. Buchanan about choosing medications for ADHD in 2017, and she is back now with an update. In addition to this interview, check out the table below for an overview of ADHD medications over the past decade. CCPR: Thanks for talking with us, Dr. Buchanan. Please help us make sense of the many new ADHD medications. Dr. Buchanan: Sure.

Viloxazine (Qelbree): A Faster Strattera?

Topics: ADHD Attention Deficit Hyperactivity Disorder | ADHD-RS-5 | CGI | Clinical Global Impressions | Post-hoc Analysis ADHD Rating Scale-5 | Qelbree | Viloxazine | Weiss Functional Impairment Rating Scale-Parent (WFIRS-P)

On April 2 viloxazine, brand name Qelbree, received an FDA indication for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents ages 6–17 years. Viloxazine is a norepinephrine reuptake inhibitor, similar to atomoxetine (Strattera), which was approved in 2008. Atomoxetine, while approved for ADHD, has some disadva

Viloxazine for ADHD

Topics: ADHD | Atomoxetine | Attention Deficit Hyperactivity Disorder | Qelbree | Research Update | Viloxazine

Review of: Nasser A et al, Int J Clin Pract 2021;75(8):e14330 Study type: Meta-analysis of randomized controlled trials Viloxazine (Qelbree) just got FDA approval in 2021 for the treatment of ADHD in children and adolescents, and the FDA is reviewing data in adult ADHD. Viloxazine has a long history of use as an antidepressant in Europe. Like atomoxet